IP Library Granted Patent US 7,232,818
Granted Patent B2
US 7,232,818 · App. 11/106,879 · Granted Jun 19, 2007

Compounds for enzyme inhibition

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,232,818
App. No.
11/106,879
Granted
Jun 19, 2007
Kind
B2
Abstract

Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation.

Claims (90)

1. A compound having a amacuire of formula (I) or a pharmaceutically acceptable salt thereof,

wherein each A is independantly selected from C═O, C═S, and SO 2 ; or

A is optionally a covalent bond when adjacent to an occurrence of Z;

L in absent or is selected from C═O, C═S, and SO 2 ;

M is absent or is C 1-12 alkyl;

Q is absent or is selected from O, NH, and N—C 1-6 alkyl;

X is selected from O, NH, and N—C 1-6 alkyl;

Y is absent or is selected from O, NH, N—C 1-6 alkyl, S, SO, SO 2 , CHOR 10 , and CHCO 2 R 10 ;

each Z is independently selected from O, S, NH, and N—C 1-6 alkyl; or

Z is optionally a covalent bond when adjacent to an occurrence of A;

R 1 , R 2 , R 3 , and R 4 are each independently selected from C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, aryl, and C 1-6 aralkyl, any of which is optionally substituted with one or more of amide, amine, caiboxylic acid (or a salt thereof), ester, thiol, or thioether substituents;

R 5 is N(R 6 )LQR 7 ;

R 6 is selected from hydrogen, OH, and C 1-6 alkyl;

R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, C 1-6 aralkyl, heteroaryl, C 1-6 heteroaralkyl, R 8 ZAZ-C 1-8 alkyl-, R 11 Z-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-ZAZ-C 1-6 alkyl-, R 8 ZAZ-C 1-8 alkyl-ZAZ-C 1-8 alkyl-, heterocyclylMZAZ-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-, (R 10 ) 2 N—C 1-12 alkyl-, (R 10 ) 3 N + -C 1-12 alkyl-, heterocyclylM-, carbocyclylM-, R 11 SO 2 C 1-8 alkyl-, and R 11 SO 2 NH; or

R 6 and R 7 together are C 1-6 alkyl-Y—C 1-6 alkyl, C 1-6 alkyl-ZAZ-C 1-6 alkyl, ZAZ-C 1-6 alkyl-ZAZ-C 1-6 alkyl, ZAZ-C 1-6 alkyl-ZAZ, or C 1-6 alkyl-A, thereby forming a ring;

R 8 and R 9 are independently selected from hydrogen, metal cation, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, heteroaryl, C 1-6 aralkyl, and C 1-6 heteroaralkyl, or R 8 and R 9 together are C 1-6 alkyl, thereby forming a ring;

each R 10 is independently selected from hydrogen and C 1-6 alkyl; and

R 11 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, carbocyclyl, heterocyclyl, aryl, heteroaryl, C 1-6 aralkyl, and C 1-6 heteroaralkyl,

provided that when R 6 is H or CH 3 and Q is absent, LR 7 is not hydrogen, unsubstituted C 1-6 alkylC═O, a further chain of amino acids, t-butoxycarbonyl (Boc), beozoyl (Bz), fluoren-9-ylmethoxycarbonyl (Fmoc), triphenylmethyl(trityl), benzyloxycarbonyl (Cbz), trichloroethoxycarbonyl (Troc); or substituted or unsubstituted aryl or heteroaryl; and

in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.

2. A compound of claim 1 , wherein R 1 , R 2 R 3 , and R 4 are independently selected from C 1-6 alkyl and C 1-6 aralkyl.

3. A compound of claim 2 , wherein R 1 and R 3 are both C 1-6 aralkyl and both R 2 and R 4 are C 1-6 alkyl.

4. A compound of claim 3 , wherein X is O, R 1 is 2-phenylethyl, R 2 is isobutyl, R 3 is phenylmethyl, and R 4 is isobutyl.

5. A compound of claim 4 , wherein L and Q are absent and R 6 is C 1-6 alkyl.

6. A compound of claim 5 , wherin R 7 is selected from C 1-6 alkyl. C 1-6 alkenyl, C 1-6 alkynyl, C 1-6 aralkyl, and C 1-6 heteroaralkyl.

7. A compound of claim 6 , wherein R 7 is C 1-6 alkyl.

8. A compound of claim 7 , wherein R 7 is butyl.

9. A compound of claim 6 , wherein R 7 is C 1-6 alkenyl.

10. A compound of claim 9 , wherein R 7 is allyl.

11. A compound of claim 6 , wherein R 7 is C 1-6 alkynyl.

12. A compound of claim 11 , wherein R 7 is propargyl.

13. A compound of claim 6 , wherein R 7 is C 1-6 aralkyl.

14. A compound of claim 13 , wherein R 7 is phenylmethyl.

15. A compound of claim 6 , wherein R 7 is C 1-6 heteroaralkyl.

16. A compound of claim 15 , wherein R 7 is selected from 2-pyridyl, 3-pyridyl, and 4-pyridyl.

17. A compound of claim 4 , wherein Q is absent and L is SO 2 .

18. A compound of claim 17 , wherein R 7 is selected from C 1-6 alkyl and C 1-6 aralkyl.

19. A compound of claim 18 , wherein R 7 is C 1-6 alkyl.

20. A compound of claim 19 , wherein R 7 is methyl.

21. A compound of claim 18 , wherein R 7 is C 1-6 aralkyl.

22. A compound of claim 21 , wherein R 7 is phenyl.

23. A compound of claim 4 , wherein L is C═O.

24. A compound of claim 23 , wherein R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, C 1-6 aralkyl, heteroaryl, C 1-6 hetcroaralkyl, R 8 ZA-C 1-8 alkyl-, R 11 Z-C 1-8 alkyl (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-ZAZ-C 1-6 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-6 alkyl-Z-C 1-8 alkyl-, R 8 ZA-C 1-8 alkyl-ZAZ-C 1-8 alkyl, heterocyclylMZAZ-C 1-8 alkyl, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-, (R 10 ) 2 N—C 1-8 alkyl-, (R 10 ) 3 N ++ —C 1-8 alkyl-, heterocyclylM-, carbocyclylM-, R 11 SO 2 C 1-8 alkyl-, and R 11 SO 2 NH; or

R 6 and R 7 together are C 1-6 alky-Y—C 1-6 alkyl, C 1-6 alkyl-ZA-C 1-6 alkyl, A-C 1-6 alkyl-ZA-C 1-6 alkyl, A-C 1-6 alkyl-A or C 1-6 alkyl-A, thereby fomiing a ring;

and each occurrence of Z and A is independently other than a covalent bond.

25. A compound of claim 24 , wherein Q is absent.

26. A compound of claim 25 , wherein R 6 and R 7 are C 1-6 alkyl.

27. A compound of claim 26 , wherein R 7 is selected from ethyl, isopropyl, 2,2,2-trifluoroethyl, and 2-(methylsulfonyl)ethyl.

28. A compound of claim 25 , wherein R 7 is C 1-6 aralkyl.

29. A compound of claim 28 , wherein R 7 is selected from 2-phenylethyl, phenylmethyl, (4-methoxyphenyl)methyl, (4-chlorophenyl)methyl, and (4-fluorophenyl)methyl.

30. A compound of claim 25 , wherein R 6 is C 1-6 alkyl and R 7 is aryl.

31. A compound of claim 30 , wherein R 7 is substituted or unsubstituted phenyl.

32. A compound of claim 24 , wherein Q is absent or O and R 7 is carbocyclylM-.

33. A compound of claim 32 , wherein carbocyclyl is cyclopropyl or cyclohexyl.

34. A compound of claim 25 , wherein R 7 is selected from R 8 ZA-C 1-6 alkyl-, R 11 Z-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-ZAZ-C 1-8 alkyl, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-Z-C 1-8 alkyl-, R 8 ZA-C 1-8 alkyl-ZAZ-C 1-8 alkyl-, heteroeyclylMZAZ-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-, A is C═O, and Z is O or NH.

35. A compound of claim 34 , wherein Z is O.

36. A compound of claim 35 , wherein R 7 is heterocyclylMZAZ-C 1-8 alkyl- and heterocyclyl is oxodioxolenyl or N(R 12 )(R 13 ), wherein R 12 and R 13 together arc C 1-6 alkyl-Y—C 1-6 alkyl, thereby forming a ring.

37. A compound of claim 36 , wherein R 7 is selected from (R 10 ) 2 N—C 1-8 alkyl- and (R 10 ) 3 N + (CH 2 ) n —, and R 10 is C 1-6 alkyl.

38. A compound of claim 25 , wherein R 7 is heterocyclylM- and hetercyclyl is selected from morpholino, piperidino, piperazino, and pyrrolidino.

39. A compound of claim 24 , wherein Q is O or NH.

40. A compound of claim 39 , wherein R 6 is C 1-6 alkyl and R 7 is selected from C 1-6 alkyl, C 1-6 aralkyl, and C 1-6 heteroaralkyl.

41. A compound of claim 40 , wherein R 7 is selected from methyl, ethyl, isopropyl, phenylmethyl, and (4-pyridyl)methyl.

42. A compound of claim 24 , wherein R 6 and R 7 together are C 1-6 alkyl-Y—C 1-6 alkyl, C 1-6 alkyl-ZA-C 1-6 alkyl, or C 1-6 alkyl-A, thereby forming a ring.

43. A compound of claim 42 , wherein L is C═O, Q and Y are absent, and R 6 and R 7 together are C 1-3 alkyl-Y—C 1-3 alkyl.

44. A compound of claim 1 , wherein L and Q are absent, and R 6 and R 7 together are C 1-3 alkyl-Y—C 1-3 alkyl.

45. A compound of claim 42 , wherein L is C═O, Q is absent, Y is selected from NH and N—C 1-6 alkyl, and R 6 and R 7 together are C 1-3 alkyl-Y—C 1-3 alkyl.

46. A compound of claim 42 , wherein L is C═O, Y is absent and R 6 and R 7 together are C 1-2 alkyl-Y—C 1-3 alkyl.

47. A compound of claim 42 , wherein L and A are C═O and R 6 and R 7 together are C 1-2 alkyl-ZA-C 1-2 alkyl.

48. A compound of claim 42 , wherein L and A are C═O and R 6 and R 7 together are C 2-3 alkyl-A.

49. A compound having a structure of formula II or a pharmaceutically acceptable salt thereof,

wherein each A is independently selected from C═O, C═S, and SO 2 ; or

A is optionally a covalent bond when adjacent to an occulTence of Z;

L is absent or is selected from C═O, C═S, and SO 2 ;

M is absent or is C 1-12 alkyl;

Q is absent or is selected from O, NH, and N—C 1-6 alkyl;

X is selected from O, NH, and N—C 1-6 alkyl;

Y is absent or is selected from O, NH, N—C 1-6 alkyl, S, SO, SO 2 , CHOR 10 , and CHCO 2 R 10 ;

each Z is independently selected from O, S, NH, and N—C 1-6 alkyl; or

Z is optionally a covalent bond when adjacent to an occunence of A;

R 2 and R 4 are each independently selected from C 1-6 alkyl, C 1-6 hydroxyalkyl, C 1-6 alkoxyalkyl, aryl, and C 1-6 aralkyl, any of which is optionally substituted with one or more of amide, amine, carboxylic acid (or a salt thereof), ester, thiol, or thioether substituents;

R 5 is N(R 6 )LQR 7 ;

R 6 is selected from hydrogen, OH, and C 1-6 alkyl;

R 7 is selected from hydrogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, C 1-6 aralkyl, heteroaryl, C 1-6 heteroaralkyl, R 11 ZAZ-C 1-8 alkyl-, R 11 Z-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-ZAZ-C 1-6 alkyl-, R 8 ZAZ-C 1-8 alkyl-ZAZ-C 1-8 alkyl-, heteroeyelylMZAZ-C 1-8 alkyl-, (R 8 O)(R 9 O)P(═O)O—C 1-8 alkyl-; (R 10 ) 2 N—C 1-12 alkyl-, (R 10 ) 3 N—C 1-12 alkyl, heterocyclylM-, carbocyclylM-, R 11 SO 2 C 1-8 alkyl-, and R 11 SO 2 NH; or

R 6 and R 7 together are C 1-6 alkyl-Y—C 1-6 alkyl, C 1-6 alkyl-ZAZ-C 1-6 alkyl, ZAZ-C 1-6 alkyl-ZAZ-C 1-6 alkyl, ZAZ-C 1-6 alkyl-ZAZ, or C 1-6 alkyl-A;

R 8 and R 9 are independently selected from hydrogen, metal cation, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, aryl, heteroaryl, C 1-6 aralkyl, and C 1-6 heteroaralkyl, or R 8 and R 9 together are C 1-6 alkyl, thereby forming a ring;

each R 10 is independently selected from hydrogen and C 1-6 alkyl; and

R 11 is independently selected from hydrogen, C 1-6 alkyl, C 1-6 alkenyl, C 1-6 alkynyl, carbocyclyl, hoterocyclyl, aryl, heteroaryl, C 1-6 aralkyl, and C 1-6 heteroaralkyl,

provided that when R 6 is H or CH 3 and Q is absent, LR 7 is not hydrogen, unsubstituted C 1-6 alkylC═O, a further chain of amino acids, t-butoxycarbonyl (Boc), benzoyl (Bz), fluoren-9-ylmethoxycarbonyl (Fmoc), triphenylmethyl(trityl), benayloxycarbonyl (Cbz), trichloroethoxycarbonyl (Troc); or substituted or unsubstituted aryl or heteroaryl; and

in any occurrence of the sequence ZAZ, at least one member of the sequence must be other than a covalent bond.

50. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

Assignments (4)
CHANGE OF ADDRESS OF THE ASSIGNEE Recorded Nov 2, 2016
From: ONYX THERAPEUTICS, INC.
To: ONYX THERAPEUTICS, INC.
Reel/Frame 040878/0943 →
MERGER Recorded May 14, 2010
From: PROTEOLIX, INC.
To: ONYX THERAPEUTICS, INC.
Reel/Frame 024380/0824 →
ASSIGNEE ADDRESS CHANGE Recorded Apr 30, 2009
From: PROTEOLIX, INC.
To: PROTEOLIX, INC.
Reel/Frame 022868/0325 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 24, 2005
From: SMYTH, MARK S.; LAIDIG, GUY J.; BORCHARDT, RONALD T.; BUNIN, BARRY A.; CREWS, CRAIG M.; MUSSER, JOHN H.; SCHNEEKLOTH, JOHN S., JR.; CHABALA, JOHN CLIFFORD
To: PROTEOLIX, INC.
Reel/Frame 016667/0869 →